TuHURA Biosciences (HURA) to Release Quarterly Earnings on Wednesday

TuHURA Biosciences (NASDAQ:HURA) will likely be issuing its quarterly earnings data before the market opens on Wednesday, February 26th. Analysts expect the company to announce earnings of ($0.09) per share for the quarter.

TuHURA Biosciences Trading Down 12.9 %

Shares of HURA stock opened at $2.90 on Tuesday. The firm’s fifty day simple moving average is $4.35. TuHURA Biosciences has a 1 year low of $2.84 and a 1 year high of $14.60.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in TuHURA Biosciences stock. Bank of America Corp DE bought a new position in TuHURA Biosciences (NASDAQ:HURA) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 14,314 shares of the company’s stock, valued at approximately $59,000. Institutional investors and hedge funds own 0.62% of the company’s stock.

Wall Street Analysts Forecast Growth

HURA has been the topic of several research analyst reports. RODMAN&RENSHAW raised shares of TuHURA Biosciences to a “strong-buy” rating in a report on Thursday, December 19th. Maxim Group initiated coverage on shares of TuHURA Biosciences in a report on Tuesday, November 5th. They issued a “buy” rating and a $15.00 price target on the stock. Finally, Rodman & Renshaw initiated coverage on shares of TuHURA Biosciences in a report on Thursday, December 19th. They issued a “buy” rating and a $11.00 price target on the stock.

About TuHURA Biosciences

TuHURA Biosciences, Inc (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.